| Last | Chg. % | Chg. Abs. | ISIN | Date, Time | MPQ |
|---|---|---|---|---|---|
| 50.2000 | -3.83% | -2.0000 | ATMARINOMED6 | 02/01/2023, 13:13:21 | C |
Ad-Hoc news provided via OAM Issuer Info Center (IIC) of OeKB (issuerinfo.oekb.at) are displayed.
Companies of the Vienna MTF/direct market are not obliged to submit their announcements to the OAM Issuer Info Center (IIC) of OeKB.
Marinomed AG - AUSTRIAN STOCK TALK | 2022 English
Published on 05/03/2022
CEO of Marinomed AG Andreas Grassauer
talks about the company and presents recent figures and facts.
Marinomed Biotech AG is a biopharmaceutical company. It specializes in the development of innovative products based on patent protected technology platforms in the field of respiratory and ophthalmic diseases. Marinomed has received multiple prestigious research awards for its activities.
Marinomed Biotech AG announced that a nasal spray with iota-carrageenan, which is identical to Marinomed’s Carragelose®, showed significant efficacy in the prevention of COVID-19 in hospital staff who manage patients with this disease. These were the results of an independent and investigator-initiated study conducted by an Argentinian research group.
#investment #biotechnology #lifesciences
More info about the stock: https://www.wienerborse.at/en/market-data/shares-others/quote/?ISIN=ATMARINOMED6&ID_NOTATION=244740791&cHash=099c0f25a925690c1be7077ca729849a
Stay updated on the Vienna Stock Exchange
➡️ Learn more: https://www.wienerborse.at/en/
➡️ Subscribe to our newsletters https://www.wienerborse.at/en/service/email-and-newsletter-service/
Follow us on social media and learn more
➡️ Twitter: https://twitter.com/wiener_boerse
➡️ LinkedIn: https://www.linkedin.com/company/wiener-borse-ag/
➡️ YouTube: https://www.youtube.com/channel/UCXqq_RYN8oNMEs1fUNefV-Q 
| Date & Feature |
|---|
No results found. |
The interviews have been conducted by Börsenradio.at and are provided in a prime version.